iRhythm Holdings Announces Third Quarter 2026 Financial Results

SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.

Third Quarter 2026 Financial Highlights * Revenue of $221.6 million, a 14.9% increase compared to third quarter 2025 * Gross margin of 74.2%, a 310-basis point increase compared to third quarter 2025 * GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared to third quarter 2025 * Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%, respectively, a $29.6 million and 1,190-basis point improvement, respectively, compared to third quarter 2025 * Unrestricted cash, cash equivalents, and marketable securities of $560.7 million as of September 30, 2026 * Increased fiscal year 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0% Recent Operational Highlights * Delivered another strong quarter, driven by healthy volume-led revenue growth of Zio Monitor and robust margin expansion, with broad-based momentum across cardiology, primary care, innovative channels and international markets * Completed the acquisition of VitalConnect on October 5, 2026, broadening our cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering, advancing our multi-vitals strategy, and expanding our addressable market across the continuum of care * Published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT(1)), Zio Long-Term Continuous Monitoring (EXCALIBUR(2)), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT(3) in over 1.7 million total patients * Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long-term continuous monitoring business * Closed a new $300 million senior secured revolving credit facility on November 3, 2026, providing additional liquidity to support our long-term growth objectives “Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. We also continued to take meaningful steps forward with significant margin expansion, and consistent execution against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “With the acquisition of VitalConnect now closed, we are encouraged by the early opportunities we see to broaden our capabilities and serve more patients within the ambulatory cardiac monitoring market and across the continuum of care. With an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be able to offer the marketplace a best-in-class MCT portfolio of options. We remain focused on advancing innovation, expanding access to Zio, and investing in the growth initiatives that we believe will create durable value for patients, clinicians, and stockholders.”